Validated MDA-MB-231 Xenograft Model:

Subcutaneous, Orthotopic, And Metastatic Xenograft Tumor Model

By Altogen Labs, 11200 Menchaca Road, Suite 203, Austin, TX 78748
Phone: (512) 433-6177 | Email: info@altogenlabs.com

Advancing Breast Cancer Research Through Xenograft Models

Breast cancer is a common and heterogeneous disease characterized by uncontrolled cell growth in the breast tissue, often classified by molecular markers such as estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. These markers guide treatment decisions and prognosis. The disease can be localized or metastatic, with early detection being critical for better outcomes. Xenograft models, where human breast cancer cells are implanted into immunocompromised mice, are essential tools for studying tumor behavior and testing therapies. Patient-derived xenografts (PDX) offer a more accurate representation of human breast cancer, preserving its genetic and molecular traits. These models are widely used for drug testing, resistance studies, and understanding tumor heterogeneity, ultimately advancing breast cancer research and treatment.

MDA-MB-231 Cell Line

The MDA-MB-231 cell line is a human breast cancer cell line derived from a pleural effusion of a 51-year-old Caucasian female with metastatic mammary adenocarcinoma. This cell line is commonly used in breast cancer research due to its ability to mimic key features of the disease, including uncontrolled cell proliferation, invasion, and metastasis. Unlike other breast cancer cell lines, MDA-MB-231 cells are triple-negative, meaning they do not express estrogen receptors (ER), progesterone receptors (PR), or HER2, which makes them particularly valuable for studying therapies targeting this subset of breast cancer. MDA-MB-231 cells are relatively easy to culture, allowing researchers to grow them in large quantities for experimental studies. Their responsiveness to various cytokines, growth factors, and other stimuli makes them a useful model for investigating factors that influence cancer cell growth, survival, and metastasis. Additionally, these cells have been employed in drug screening, tumor microenvironment studies, and xenograft models, contributing to the development of targeted therapies and a better understanding of metastatic breast cancer. Their versatility and relevance to clinical research continue to make them a vital tool in the study of breast cancer biology.



Figure 1. Tumor Histology. H&E stained slide of a subcutaneously-implanted MDA-MB-231 tumor (Altogen Labs).

Altogen Labs Validated MDA-MB-231 Xenograft Model

Cells are cultured under strict aseptic conditions and maintained in the exponential growth phase until they are ready for collection. During this phase, the cells are monitored for optimal growth conditions, ensuring they remain healthy and viable for experimental purposes. Once the cells are harvested, their viability is determined using the trypan blue exclusion assay, which is a reliable method for assessing cell health. A minimum viability of 98% is required to ensure the accuracy and reproducibility of the study results. After confirming the viability, the cell suspension is adjusted by volume to achieve the desired concentration. For each injection, 100 µL of Matrigel mixed with MDA-MB-231 cells is prepared, containing exactly one million cells. This cell suspension is then inoculated subcutaneously (s.c.) into the flank of one hind leg of each mouse, ensuring consistent and precise tumor inoculation.



Figure 2. MDA-MB-231 breast cancer xenografted in immunocompromised mice, mean values +/- SEM (Altogen Labs).

The animals used in the study are 10–12 week-old NOD/SCID or athymic BALB/C mice, which are immunocompromised and allow for the successful engraftment of human cancer cells. Tumor growth is closely monitored through daily caliper measurements, which help to track tumor size and determine the appropriate time to start the study. The tumors are expected to grow to a size range of 50-150 mm^3 before the treatment protocol begins. Following tumor growth monitoring, the animals are sorted into treatment cohorts, and test compounds are administered according to a predefined treatment schedule. Throughout the study, tumor measurements are recorded daily to monitor the effects of the treatments. The study is completed once the tumors reach a specified size limit as outlined in the study plan. At the conclusion of the study, necropsies are performed for tumor removal, and tumor weights are carefully recorded and documented digitally for further analysis. Tumors and surrounding tissues are preserved for future examination, with options for snap freezing in liquid nitrogen, stabilization in RNAlater, or nucleic acid isolation. This comprehensive approach ensures that high-quality data is generated to evaluate the efficacy of the test compounds and provides valuable insights into cancer biology and treatment response.



Figure 3. Tumor weight of MDA-MB-231 cells in control, non-treatment mice and herceptin treated mice at end of the study (Altogen Labs).

Subcutaneous MDA-MB-231 Breast Cancer Xenograft Model

The subcutaneous MDA-MB-231 model involves the injection of MDA-MB-231 human breast cancer cells into the flank of immunocompromised mice, where they form a primary tumor under the skin. This model is widely used to study tumor growth, therapeutic efficacy, and the effects of various treatments on breast cancer. Since the tumor grows outside the body, it is easy to monitor and measure, providing a reliable method for assessing tumor size and response to interventions. The subcutaneous MDA-MB-231 model is particularly valuable for preclinical drug testing and evaluating novel therapeutic agents. Researchers can use this model to investigate various molecular pathways involved in tumor progression, angiogenesis, and drug resistance. It also provides an opportunity to test combinations of therapies or investigate the impact of genetic modifications on tumor behavior.

Mimicking Human Breast Cancer with the Orthotopic MDA-MB-231 Model

The orthotopic MDA-MB-231 model involves the implantation of MDA-MB-231 human breast cancer cells into the mammary fat pad of immunocompromised mice, closely mimicking the natural environment of breast cancer growth. This model is commonly used to study the tumor microenvironment, tumor growth, and metastasis, as the cells maintain key characteristics of the primary tumor, such as invasiveness and hormone receptor-negative status. By injecting cells suspended in Matrigel, researchers can observe the development of both local and distant metastases, such as lung, liver, and lymph node involvement. The orthotopic MDA-MB-231 model is especially valuable for testing therapies targeting primary tumors and metastatic disease, as it replicates key aspects of human breast cancer. Tumor growth is monitored regularly by calipering, and metastasis is assessed using imaging techniques or histological analysis. This model is widely used in drug discovery and for understanding the mechanisms of cancer progression. The ability to study both the primary tumor and its metastases in a relevant, physiological context makes the orthotopic MDA-MB-231 model an essential tool in preclinical cancer research.

Evaluating Metastatic Breast Cancer Progression Using MDA-MB-231

The metastatic MDA-MB-231 model involves injecting MDA-MB-231 human breast cancer cells into immunocompromised mice, allowing researchers to study the full metastatic process, from primary tumor growth to distant organ spread. This model is particularly useful for studying triple-negative breast cancer, as MDA-MB-231 cells lack estrogen, progesterone, and HER2 receptors, making them highly aggressive and prone to metastasis. Once injected, the cells form primary tumors in the mammary fat pad, and metastasis is monitored in organs such as the lungs, liver, and lymph nodes. Researchers can assess tumor growth, metastasis, and response to therapeutic interventions using imaging techniques, histology, and molecular markers. The metastatic MDA-MB-231 model is a valuable preclinical tool for evaluating treatments aimed at preventing or treating metastatic breast cancer. It helps in understanding the molecular mechanisms

driving metastasis, such as epithelial-mesenchymal transition (EMT) and angiogenesis. This model is frequently used in drug discovery, particularly for developing therapies targeting both the primary tumor and metastatic sites. The ability to observe the entire metastatic cascade in a relevant biological context makes it an indispensable model in cancer research.

Case Study: Sphingosine Kinase Activity is Dispensable for MDA-MB-231 Survival

A study conducted by Rex K, *et al.* published by *PLOS One* journal, investigates whether sphingosine kinase (SPHK) activity is essential for the viability of MDA-MB-231, a triple-negative breast cancer (TNBC) cell line, and other tumor cells. SPHKs produce sphingosine-1-phosphate (S1P), a signaling lipid implicated in cell survival, proliferation, and tumor progression. The rheostat theory suggests that SPHK activity shifts the balance from pro-apoptotic sphingolipids to mitogenic S1P, thereby promoting cancer cell survival. Using SPHK1/2 inhibitors, researchers successfully blocked intracellular S1P production in MDA-MB-231 and other cell lines. Surprisingly, this did not lead to a reduction in cell viability *in vitro* or tumor growth *in vivo*. Further validation using siRNA knockdown of SPHK1 and SPHK2 in multiple tumor cell lines, including MDA-MB-231, failed to show significant effects on viability, contradicting the expected role of SPHK in apoptosis regulation. In xenograft models, MDA-MB-231 tumors in mice continued to grow despite SPHK inhibition, while positive controls like Docetaxel effectively suppressed tumor growth. Additionally, vascular permeability assays confirmed that SPHK inhibition influenced angiogenesis-related pathways but not direct tumor cell viability. The findings suggest that SPHKs are not essential for MDA-MB-231 cell survival, challenging their validity as therapeutic targets in oncology.

Alternative Chemotherapies: Foretinib Suppresses MDA-MB-231 Triple-Negative Breast Cancer Growth

Foretinib, a small-molecule kinase inhibitor, shows significant potential in treating triple-negative breast cancer (TNBC) by targeting MDA-MB-231 cells. TNBC is a highly aggressive subtype with limited treatment options, often driven by overactive p-MET/HGF signaling. This study demonstrates that foretinib effectively inhibits tumor growth both *in vitro* and *in vivo* by downregulating phosphorylated MET (p-MET) and hepatocyte growth factor (HGF), which are crucial for cancer cell proliferation and metastasis. In a mouse xenograft model, foretinib administration resulted in a dose-dependent reduction in tumor size without significant toxicity. Western blot and immunohistochemical analyses confirmed a decrease in p-MET and HGF expression, indicating that MET inhibition is a viable therapeutic strategy for TNBC. Additionally, pharmacokinetic analysis revealed that foretinib is rapidly metabolized, supporting its potential as a well-tolerated treatment. These findings suggest that targeting the MET pathway with foretinib could provide an effective therapeutic avenue for patients with TNBC, especially those with MET-overexpressing tumors.

Additional Case Study: Targeting Cancer Stem Cells in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) remains a difficult-to-treat subtype, often driven by aggressive cancer stem cells (CSCs). In a study by Tanei, T., *et al.*, published by *Breast Cancer Research* journal, researchers investigated the effects of the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody Cetuximab, alone and in combination with Ixabepilone, in TNBC models using the MDA-MB-231 and SUM159 cell lines. Cetuximab effectively reduced the CSC population in both cell lines, as indicated by decreases in CD44+/CD24-/low and Aldefluor+ cells, key markers of stemness. Additionally, the study found that Cetuximab inhibited autophagy-related survival mechanisms in CSCs, further limiting their ability to regenerate. However, while Cetuximab alone showed promise, the combination therapy with Ixabepilone yielded significant improvements in tumor growth suppression only in SUM159 tumors, but not in MDA-MB-231 xenografts. These findings suggest that while targeting EGFR can impair CSC function, its therapeutic efficacy may be influenced by TNBC subtype-specific factors. The study underscores the importance of personalized treatment approaches in TNBC, as certain subpopulations, like MDA-MB-231, may require alternative or additional therapeutic strategies.



Figure 4. Treating MDA-MB-231 xenografted tumors with cetuximab (50 µg/ml) resulted in significant inhibition of tumor growth.

Targeting Mitochondrial ncRNA to Halt Breast Cancer Growth

A novel approach to treating triple-negative breast cancer (TNBC) focuses on targeting mitochondrial noncoding RNAs (ncmtRNAs) in MDA-MB-231 cells. Researchers found that knocking down specific antisense mitochondrial RNAs (ASncmtRNAs) triggers a powerful anti-cancer effect by inducing cell cycle arrest and apoptosis. This mechanism works by downregulating key cell cycle proteins, including cyclin B1, cyclin D1, CDK1, CDK4, and survivin, which are essential for cancer cell proliferation. The treatment also increases specific microRNAs that further suppress these cell cycle regulators, amplifying the tumor-suppressive response. In a mouse xenograft model, this approach led to a significant reduction in tumor growth, demonstrating its potential as a therapeutic strategy. Importantly, this targeted intervention does not harm normal cells, making it a promising avenue for developing safer, more effective breast cancer treatments.

DEK Oncogene Knockdown Reduces Redox State and Invasiveness in MDA-MB-231 Cells

The DEK oncogene plays a significant role in the aggressiveness of MDA-MB-231 breast cancer cells by influencing their redox state and invasive potential. DEK is a chromatin remodeling protein that is overexpressed in many cancers, including breast cancer, and is associated with increased proliferation, invasion, and metastasis. Optical redox imaging (ORI) studies have shown that MDA-MB-231 cells exhibit a high FAD redox ratio, correlating with their aggressive nature. When DEK expression is knocked down, these cells display a significantly lower redox ratio and reduced invasive potential, indicating that DEK contributes to metabolic reprogramming in cancer cells. DEK overexpression promotes an oxidized redox state, likely through its influence on mitochondrial metabolism and NAD-coupled redox balance. The study found that DEK knockdown reduced FAD fluorescence intensity and the FAD redox ratio, suggesting a shift toward a more reduced mitochondrial state. These findings further reinforce the link between oncogene activity and cellular metabolism in breast cancer. Given DEK's role in tumor progression, it is considered a potential therapeutic target for inhibiting metastasis and improving treatment outcomes in triple-negative breast cancer.

Altogen Labs offers a comprehensive range of preclinical oncology services, utilizing over 90 standard Cell Line-Derived Xenograft (CDX) models and 30 Patient-Derived Xenograft (PDX) models. These models support research into tumor biology, therapeutic efficacy, and the role of specific gene products in cancer progression. Custom cell line development services include protein overexpression models (ectopic expression of oncogenes or tumor suppressors) and RNAi-based gene silencing for long-term functional studies. Additionally, Altogen Labs provides quantitative gene expression analysis via RT-PCR and protein expression profiling using the WES system.



Figure 5. MDA-MB-231 *in vivo* xenograft services at Altogen Labs (Altogen Labs).

Animal studies at Altogen Labs adhere to IACUC regulations and GLP standards, ensuring high-quality, ethically compliant research. Mice are acclimated, sorted by body mass, and monitored daily for tumor development and clinical health. Comprehensive experimental reports include methodology, statistical analysis, and raw data. Additional services encompass histology, gene expression analysis, protein/RNA isolation, and specialized dietary protocols for inducible gene expression studies. For MDA-MB-231 xenograft models, available study endpoints include tumor growth delay (TGD), tumor growth inhibition (TGI), pharmacokinetics, toxicity, survival analysis, and metabolic assays. Drug administration options range from systemic (IV, oral gavage, intraperitoneal) to targeted (intratumoral, orthotopic, mammary fat pad, or tail vein injection for metastasis studies). Imaging modalities such as fluorescence-based whole-body imaging further enhance data collection, while control cohorts can receive cyclophosphamide (20-40 mg/kg IM) to benchmark therapeutic response.

References:

Fitzpatrick, C., Bendek, M.F., Briones, M. *et al.* Mitochondrial ncRNA targeting induces cell cycle arrest and tumor growth inhibition of MDA-MB-231 breast cancer cells through reduction of key cell cycle progression factors. *Cell Death Dis* 10, 423 (2019). https://doi.org/10.1038/s41419-019-1649-3

Ji, X., Meng, X., He, Q., Xiang, X., Shi, Y., & Zhu, X. (2023). Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling. *International Journal of Molecular Sciences*, *24*(1), 757. https://doi.org/10.3390/ijms24010757

MDA-MB-231. https://altogenlabs.com/xenograft-models/breast-cancer-xenograft/mda-mb-231-xenograft-model/

Rex K, Jeffries S, Brown ML, Carlson T, Coxon A, Fajardo F, Frank B, Gustin D, Kamb A, Kassner PD, Li S, Li Y, Morgenstern K, Plant M, Quon K, Ruefli-Brasse A, Schmidt J, Swearingen E, Walker N, Wang Z, Watson JE, Wickramasinghe D, Wong M, Xu G, Wesche H. Sphingosine kinase activity is not required for tumor cell viability. *PLoS One*. 2013 Jul 5;8(7):e68328. doi: 10.1371/journal.pone.0068328. PMID: 23861887; PMCID: PMC3702540.

Tanei, T., Choi, D.S., Rodriguez, A.A. *et al.* Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells. *Breast Cancer Res* 18, 6 (2016). https://doi.org/10.1186/s13058-015-0662-4

Keywords: MDA-MB-231, breast cancer, xenograft, breast, *in vivo*, cancer, preclinical, research, *in vivo* pharmacology, orthotopic, metastatic, CDX, PDX

Other Available Altogen Labs Validated Xenograft Models:

BT474 Xenograft Model: https://altogenlabs.com/xenograft-models/breast-cancer-xenograft/bt474-xenograft-model/

Hs578T Xenograft Model: https://altogenlabs.com/xenograft-models/breast-cancer-xenograft/hs578t-xenograft-model/

MCF7 Xenograft Model: https://altogenlabs.com/xenograft-models/breast-cancer-xenograft/mcf7-xenograft-model/

HCC1954 Xenograft Model: https://altogenlabs.com/xenograft-models/breast-cancer-xenograft/hcc1954-xenograft-model/

NCI-H460 Xenograft Model: https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/h460-xenograft-model/

NCI-H1975 Xenograft Model: https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/nci-h1975-xenograft-model/

NCI-H226 Xenograft Model: https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/nci-h226-xenograft-model/

NCI-H1155 Xenograft Model: https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/h1155-xenograft-model/